Ligand Pharmaceuticals Inc (LGND)
EBITDA
$274.03M
TTM · Period ending: · USD
LGND EBITDA
Latest reported$274.03Mperiod ending
Latest reported$274.03Mperiod ending
LGND EBITDA (-$18.40M → $274.03M)
Annual EBITDA
High-resolution chart · PNG
LGND ebitda history
Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA (USD) |
|---|---|
| 192,735,000 | |
| 40,794,000 | |
| 100,837,000 | |
| 81,204,000 | |
| 142,770,000 | |
| 56,673,000 | |
| 876,115,000 | |
| 236,324,000 | |
| 80,345,000 | |
| 55,175,000 | |
| 29,956,000 | |
| 23,367,000 | |
| 18,646,000 | |
| 3,942,000 | |
| 1,740,000 | |
| -13,133,000 | |
| -6,468,000 | |
| -96,261,000 | |
| -50,106,000 | |
| -61,863,000 | |
| -26,471,000 | |
| -18,269,000 | |
| -59,689,000 | |
| -35,131,000 | |
| -16,564,000 | |
| -38,637,000 | |
| -54,193,000 | |
| -65,100,000 | |
| -21,000,000 | |
| -23,500,000 | |
| -21,200,000 | |
| -18,400,000 |